Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Labopharm Once-Daily Tramadol Is “Approvable”

This article was originally published in The Pink Sheet Daily

Executive Summary

The Canadian firm may still have an opportunity to reach its end-of-2006 launch goal for the opioid analgesic.

You may also be interested in...

Ouch: Cipher Maintains Phase III Trial Failure Of Tramadol Will Not Impact NDA

Ontario drug maker may have to contend with two other competitors in the synthetic opioid space.

Biovail’s Tramadol ER Approved Without Additional Clinical Studies

The company expects the analgesic to launch early in 2006, but continues negotiations over a marketing partnership.

Purdue Signs On To Market Labopharm's Once-Daily Tramadol

Labopharm will receive up to $170 mil. under the licensing deal, including $20 mil. up front and $40 mil. upon NDA approval.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts